Analysis of endothelial function of patients with large vessel vasculitis and ANCA-associated small vessel vasculitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005139

Enrollment

100

Registered

2013-07-29

Start date

2013-08-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M31.5 M31.6 M31.3 M31.7 M30.1

Interventions

Group 1: large vessel vasculitis (giant cell vasculitis) or ANCA-associated small vessel vasculitis (Wegener's granulomatosis, Churg-Strauss-syndrom, microskopic polyangiitis): 1) dynamic retinal ves

6) serological inflammation markers

7) p-/c-ANCAs, PR3, MPO (ELISA)

S-Kreatinin, eGFR nach CKD-Epi, Proteinuria, blood picture, HbA1c, blood-lipids, ASAT, ALAT, GGT

8) serum-concentration of biomarkers: E-Selectin, epidermal growth factor, epidermal growth factor-like domain containing protein 7 and basic-fibroblast growth factor

9) serum-concentration of circulating endothel cells

10) serum-concentration of thombocytic microparticles

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of the department of rheumatology. Age > 18 years. Presentation of large vessel vasculitis (giant cell vasculitis) or ANCA-associated small vessel vasulitis (Wegener's granulomatosis, Churg-Strauss-syndrom, microskopic polyangiitis) independend of disease activity. Existence of a consent form.

Exclusion criteria

Exclusion criteria: Patients with another chronic-rheumatic disease or another systemic autoimmune disease. glaucoma or increased intraocular preasure. Coronary heart disease, peripherial artery disease, cerebrovascular disease, nephropathy with renal failure 4-5, diabetes mellitus, instable epilepsy, pregnancy/lactation.

Design outcomes

Primary

Measure	Time frame
1) RVA-measurement at the right eye using flickerlight after application of Tropicamid 1%: Baseline-measurement of the retinal vessels diameters for 50 seconds and measurement for 80 seconds after application of 20 seconds flickerlight. Performance of 3 of this measurement-circles. 2) EndoPAT-measurement: 5 minutes baseline-measurement and 5 minutes measurement after occlusion of the A. brachialis for a duration of 5 minutes. 3) laser-doppler-measurement: 5 minutes baseline-measurement and 5 minutes measurement after occlusion of the A. brachialis for a duration of 5 minutes. 4) ultrasound-measurement of the intima-media-thickness of the far wall of the A. carotis communis.	—

Measure

Time frame

1) RVA-measurement at the right eye using flickerlight after application of Tropicamid 1%: Baseline-measurement of the retinal vessels diameters for 50 seconds and measurement for 80 seconds after application of 20 seconds flickerlight. Performance of 3 of this measurement-circles. 2) EndoPAT-measurement: 5 minutes baseline-measurement and 5 minutes measurement after occlusion of the A. brachialis for a duration of 5 minutes. 3) laser-doppler-measurement: 5 minutes baseline-measurement and 5 minutes measurement after occlusion of the A. brachialis for a duration of 5 minutes. 4) ultrasound-measurement of the intima-media-thickness of the far wall of the A. carotis communis.

—

Secondary

Measure	Time frame
1) disease activity and course of disease: Birmingham vasculitits activity score (BVAS V3), vascular damage index (VDI), duration of disease, number/duration/severity of acute attacks; 2) serological inflammation markers; p-/c-ANCAs, PR3, MPO (ELISA); S-Kreatinin, eGFR nach CKD-Epi, Proteinuria, blood picture, HbA1c, blood-lipids, ASAT, ALAT, GGT; 3) serum-concentration of biomarkers: E-Selectin, epidermal growth factor, epidermal growth factor-like domain containing protein 7 and basic-fibroblast growth factor; 4) serum-concentration of circulating endothel cells; 5) serum-concentration of thombocytic microparticles	—

Measure

Time frame

1) disease activity and course of disease: Birmingham vasculitits activity score (BVAS V3), vascular damage index (VDI), duration of disease, number/duration/severity of acute attacks; 2) serological inflammation markers; p-/c-ANCAs, PR3, MPO (ELISA); S-Kreatinin, eGFR nach CKD-Epi, Proteinuria, blood picture, HbA1c, blood-lipids, ASAT, ALAT, GGT; 3) serum-concentration of biomarkers: E-Selectin, epidermal growth factor, epidermal growth factor-like domain containing protein 7 and basic-fibroblast growth factor; 4) serum-concentration of circulating endothel cells; 5) serum-concentration of thombocytic microparticles

—

Countries

Germany

Contacts

Public ContactThomas Neumann

Universitätsklinikum Jena Klinik für Innere Medizin 3 Rheumatologie

thomas.neumann@med.uni-jena.de+49 3641 9324595

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026